OA10842A - Methods and compositions for protective and therapeutic genetic immunization - Google Patents

Methods and compositions for protective and therapeutic genetic immunization Download PDF

Info

Publication number: OA10842A
Authority: OA; OAPI
Prior art keywords: virus; cells; cell; host; class
Prior art date: 1996-02-21

Application number

OA9800147A

Other languages

English (en)

Inventor

Julianna Lisziewicz

Franco Lori

Original Assignee

Julianna Lisziewicz

Franco Lori

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-21

Filing date

1998-08-18

Publication date

2001-08-14

1998-08-18 Application filed by Julianna Lisziewicz, Franco Lori filed Critical Julianna Lisziewicz

2001-08-14 Publication of OA10842A publication Critical patent/OA10842A/en

Links

238000000034 method Methods 0.000 title claims abstract description 88
230000002068 genetic effect Effects 0.000 title claims abstract description 64
239000000203 mixture Substances 0.000 title claims abstract description 23
238000002649 immunization Methods 0.000 title abstract description 57
230000003053 immunization Effects 0.000 title abstract description 57
230000001681 protective effect Effects 0.000 title abstract description 10
230000001225 therapeutic effect Effects 0.000 title abstract description 9
241000700605 Viruses Species 0.000 claims abstract description 314
210000004027 cell Anatomy 0.000 claims abstract description 212
230000028993 immune response Effects 0.000 claims abstract description 89
210000005210 lymphoid organ Anatomy 0.000 claims abstract description 64
210000004443 dendritic cell Anatomy 0.000 claims abstract description 48
208000036142 Viral infection Diseases 0.000 claims abstract description 25
230000014509 gene expression Effects 0.000 claims abstract description 25
238000010361 transduction Methods 0.000 claims abstract description 21
230000026683 transduction Effects 0.000 claims abstract description 21
230000009385 viral infection Effects 0.000 claims abstract description 19
241001465754 Metazoa Species 0.000 claims abstract description 13
230000002463 transducing effect Effects 0.000 claims abstract description 6
239000000427 antigen Substances 0.000 claims description 93
108091007433 antigens Proteins 0.000 claims description 93
102000036639 antigens Human genes 0.000 claims description 93
206010028980 Neoplasm Diseases 0.000 claims description 54
108010061833 Integrases Proteins 0.000 claims description 49
108090000623 proteins and genes Proteins 0.000 claims description 42
102100034343 Integrase Human genes 0.000 claims description 40
108090000695 Cytokines Proteins 0.000 claims description 37
102000004127 Cytokines Human genes 0.000 claims description 32
241001430294 unidentified retrovirus Species 0.000 claims description 23
102000004169 proteins and genes Human genes 0.000 claims description 19
230000004044 response Effects 0.000 claims description 19
230000002950 deficient Effects 0.000 claims description 18
230000035772 mutation Effects 0.000 claims description 16
238000001727 in vivo Methods 0.000 claims description 12
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 11
108010065805 Interleukin-12 Proteins 0.000 claims description 8
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 8
108090000978 Interleukin-4 Proteins 0.000 claims description 7
241000701806 Human papillomavirus Species 0.000 claims description 6
108010002350 Interleukin-2 Proteins 0.000 claims description 5
241000713666 Lentivirus Species 0.000 claims description 4
230000005867 T cell response Effects 0.000 claims description 4
102000019034 Chemokines Human genes 0.000 claims description 3
108010012236 Chemokines Proteins 0.000 claims description 3
230000004568 DNA-binding Effects 0.000 claims description 3
208000031886 HIV Infections Diseases 0.000 claims description 3
241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 3
108010002352 Interleukin-1 Proteins 0.000 claims description 3
108090000172 Interleukin-15 Proteins 0.000 claims description 3
101800003050 Interleukin-16 Proteins 0.000 claims description 3
108010002386 Interleukin-3 Proteins 0.000 claims description 3
108010002586 Interleukin-7 Proteins 0.000 claims description 3
210000003719 b-lymphocyte Anatomy 0.000 claims description 3
108700004026 gag Genes Proteins 0.000 claims description 3
101150098622 gag gene Proteins 0.000 claims description 3
101710091881 GTPase HRas Proteins 0.000 claims description 2
102100029974 GTPase HRas Human genes 0.000 claims description 2
206010038997 Retroviral infections Diseases 0.000 claims description 2
241000287219 Serinus canaria Species 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 8
101150013359 E7 gene Proteins 0.000 claims 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims 2
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 2
108090001005 Interleukin-6 Proteins 0.000 claims 2
102000001327 Chemokine CCL5 Human genes 0.000 claims 1
108010055166 Chemokine CCL5 Proteins 0.000 claims 1
101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims 1
101000815628 Homo sapiens Regulatory-associated protein of mTOR Proteins 0.000 claims 1
101000652747 Homo sapiens Target of rapamycin complex 2 subunit MAPKAP1 Proteins 0.000 claims 1
101000648491 Homo sapiens Transportin-1 Proteins 0.000 claims 1
241000713340 Human immunodeficiency virus 2 Species 0.000 claims 1
208000005074 Retroviridae Infections Diseases 0.000 claims 1
102100028748 Transportin-1 Human genes 0.000 claims 1
230000036755 cellular response Effects 0.000 claims 1
102000043600 human HRAS Human genes 0.000 claims 1
230000010076 replication Effects 0.000 claims 1
230000002238 attenuated effect Effects 0.000 abstract description 78
230000003612 virological effect Effects 0.000 abstract description 56
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 31
201000010099 disease Diseases 0.000 abstract description 30
239000002245 particle Substances 0.000 abstract description 29
230000001717 pathogenic effect Effects 0.000 abstract description 13
230000036039 immunity Effects 0.000 abstract description 12
238000011282 treatment Methods 0.000 abstract description 11
210000000987 immune system Anatomy 0.000 abstract description 10
241000282412 Homo Species 0.000 abstract description 9
230000007416 antiviral immune response Effects 0.000 abstract description 8
230000005860 defense response to virus Effects 0.000 abstract description 6
208000015181 infectious disease Diseases 0.000 description 60
108020004414 DNA Proteins 0.000 description 52
229960005486 vaccine Drugs 0.000 description 21
241000725303 Human immunodeficiency virus Species 0.000 description 19
238000002347 injection Methods 0.000 description 17
239000007924 injection Substances 0.000 description 17
210000000612 antigen-presenting cell Anatomy 0.000 description 16
210000001744 T-lymphocyte Anatomy 0.000 description 15
210000004881 tumor cell Anatomy 0.000 description 14
210000002540 macrophage Anatomy 0.000 description 13
238000004519 manufacturing process Methods 0.000 description 13
210000000056 organ Anatomy 0.000 description 12
238000002474 experimental method Methods 0.000 description 11
230000002458 infectious effect Effects 0.000 description 11
241000699670 Mus sp. Species 0.000 description 10
241000700618 Vaccinia virus Species 0.000 description 10
210000004698 lymphocyte Anatomy 0.000 description 10
230000007918 pathogenicity Effects 0.000 description 10
208000030507 AIDS Diseases 0.000 description 9
210000002865 immune cell Anatomy 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
241001529936 Murinae Species 0.000 description 8
238000003556 assay Methods 0.000 description 8
201000011510 cancer Diseases 0.000 description 8
210000002950 fibroblast Anatomy 0.000 description 8
230000006698 induction Effects 0.000 description 8
210000003071 memory t lymphocyte Anatomy 0.000 description 8
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 8
241000282693 Cercopithecidae Species 0.000 description 7
108010067390 Viral Proteins Proteins 0.000 description 7
210000000952 spleen Anatomy 0.000 description 7
238000002255 vaccination Methods 0.000 description 7
206010046865 Vaccinia virus infection Diseases 0.000 description 6
239000002502 liposome Substances 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
210000002741 palatine tonsil Anatomy 0.000 description 6
208000007089 vaccinia Diseases 0.000 description 6
201000009030 Carcinoma Diseases 0.000 description 5
230000008901 benefit Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
208000032839 leukemia Diseases 0.000 description 5
210000001165 lymph node Anatomy 0.000 description 5
238000010172 mouse model Methods 0.000 description 5
210000005259 peripheral blood Anatomy 0.000 description 5
239000011886 peripheral blood Substances 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
229940031626 subunit vaccine Drugs 0.000 description 5
239000000277 virosome Substances 0.000 description 5
241000713800 Feline immunodeficiency virus Species 0.000 description 4
241000282553 Macaca Species 0.000 description 4
241001631646 Papillomaviridae Species 0.000 description 4
101710177166 Phosphoprotein Proteins 0.000 description 4
241000714223 Rauscher murine leukemia virus Species 0.000 description 4
206010058874 Viraemia Diseases 0.000 description 4
108020005202 Viral DNA Proteins 0.000 description 4
206010022000 influenza Diseases 0.000 description 4
239000000463 material Substances 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
241001529453 unidentified herpesvirus Species 0.000 description 4
239000013598 vector Substances 0.000 description 4
210000002845 virion Anatomy 0.000 description 4
230000001018 virulence Effects 0.000 description 4
101710205625 Capsid protein p24 Proteins 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
241000714165 Feline leukemia virus Species 0.000 description 3
-1 GM-CSF Proteins 0.000 description 3
241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
208000007766 Kaposi sarcoma Diseases 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
101710149279 Small delta antigen Proteins 0.000 description 3
230000024932 T cell mediated immunity Effects 0.000 description 3
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 3
238000010171 animal model Methods 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
230000000981 bystander Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
241001493065 dsRNA viruses Species 0.000 description 3
230000006870 function Effects 0.000 description 3
230000028996 humoral immune response Effects 0.000 description 3
230000037451 immune surveillance Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000005923 long-lasting effect Effects 0.000 description 3
210000003563 lymphoid tissue Anatomy 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
244000052769 pathogen Species 0.000 description 3
230000002085 persistent effect Effects 0.000 description 3
230000003362 replicative effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000009466 transformation Effects 0.000 description 3
238000011830 transgenic mouse model Methods 0.000 description 3
230000010415 tropism Effects 0.000 description 3
230000005740 tumor formation Effects 0.000 description 3
229960004854 viral vaccine Drugs 0.000 description 3
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
241000714266 Bovine leukemia virus Species 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
208000011691 Burkitt lymphomas Diseases 0.000 description 2
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
208000003322 Coinfection Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000282324 Felis Species 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000043129 MHC class I family Human genes 0.000 description 2
108091054437 MHC class I family Proteins 0.000 description 2
206010064912 Malignant transformation Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
108010021466 Mutant Proteins Proteins 0.000 description 2
102000008300 Mutant Proteins Human genes 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
208000035415 Reinfection Diseases 0.000 description 2
MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
241000713311 Simian immunodeficiency virus Species 0.000 description 2
230000004913 activation Effects 0.000 description 2
201000006966 adult T-cell leukemia Diseases 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
230000005975 antitumor immune response Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000027455 binding Effects 0.000 description 2
238000001815 biotherapy Methods 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
210000000234 capsid Anatomy 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000001010 compromised effect Effects 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
210000004700 fetal blood Anatomy 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
210000001821 langerhans cell Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
230000036212 malign transformation Effects 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000004296 naive t lymphocyte Anatomy 0.000 description 2
108700004028 nef Genes Proteins 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
108700026215 vpr Genes Proteins 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
101710145634 Antigen 1 Proteins 0.000 description 1
244000125300 Argania sideroxylon Species 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 1
108090001069 Chymopapain Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
208000000666 Fowlpox Diseases 0.000 description 1
208000003098 Ganglion Cysts Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102100025306 Integrin alpha-IIb Human genes 0.000 description 1
206010023825 Laryngeal cancer Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
108010076039 Polyproteins Proteins 0.000 description 1
241000288906 Primates Species 0.000 description 1
101710149136 Protein Vpr Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
241001068295 Replication defective viruses Species 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
208000005400 Synovial Cyst Diseases 0.000 description 1
108010008038 Synthetic Vaccines Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
206010044696 Tropical spastic paresis Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
210000000780 bap Anatomy 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
238000012136 culture method Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000002498 deadly effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012636 effector Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000000285 follicular dendritic cell Anatomy 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
231100000118 genetic alteration Toxicity 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000008076 immune mechanism Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
244000000056 intracellular parasite Species 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
206010023841 laryngeal neoplasm Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
101710130522 mRNA export factor Proteins 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000004719 natural immunity Effects 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
101150023385 nef gene Proteins 0.000 description 1
108010062490 p27 antigen Proteins 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000011809 primate model Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001915 proofreading effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
229940124551 recombinant vaccine Drugs 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000007480 spreading Effects 0.000 description 1
208000017015 squamous papilloma Diseases 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
208000006961 tropical spastic paraparesis Diseases 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
229940125575 vaccine candidate Drugs 0.000 description 1
239000006216 vaginal suppository Substances 0.000 description 1
230000007442 viral DNA synthesis Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
101150024249 vpr gene Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Mycology (AREA)
Biophysics (AREA)
Oncology (AREA)
Hematology (AREA)
Plant Pathology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

OA9800147A 1996-02-21 1998-08-18 Methods and compositions for protective and therapeutic genetic immunization OA10842A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US60462796A	1996-02-21	1996-02-21

Publications (1)

Publication Number	Publication Date
OA10842A true OA10842A (en)	2001-08-14

Family

ID=24420371

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9800147A OA10842A (en)	1996-02-21	1998-08-18	Methods and compositions for protective and therapeutic genetic immunization

Country Status (12)

Country	Link
EP (1)	EP0882134B8 (de)
JP (1)	JP2000517290A (de)
AP (1)	AP964A (de)
AT (1)	ATE429505T1 (de)
AU (1)	AU726623B2 (de)
CA (1)	CA2246359A1 (de)
DE (1)	DE69739372D1 (de)
EA (2)	EA002020B1 (de)
ES (1)	ES2324745T3 (de)
NZ (1)	NZ331369A (de)
OA (1)	OA10842A (de)
WO (1)	WO1997031119A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3210997A (en) *	1996-05-24	1997-12-09	University Of Maryland At Baltimore	Dna vaccines for eliciting a mucosal immune response
US6797276B1 (en)	1996-11-14	2004-09-28	The United States Of America As Represented By The Secretary Of The Army	Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en)	1996-11-14	2006-01-05	Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc.	Transcutaneous immunization without heterologous adjuvant
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
NZ503334A (en) *	1997-09-15	2002-05-31	Genetic Immunity Llc	A gene delivering complex having a vector with a specific affinity for a foreign genetic material and a second site having a specific affinity for a receptor on an antigen presenting cell
JP2002508338A (ja) *	1997-12-12	2002-03-19	ナルディニ，ルイジ	レンチウィルスベクターの治療使用
WO1999047146A1 (en) *	1998-03-17	1999-09-23	Julianna Lisziwiewicz	Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor
US6461616B1 (en) *	2000-09-09	2002-10-08	Akzo Nobel Nv	EIAV p26 deletion vaccine and diagnostic
US20070025958A1 (en)	2000-10-27	2007-02-01	Hadden John W	Vaccine immunotherapy
CA2950109C (en)	2000-10-27	2019-02-19	John W. Hadden	Vaccine immunotherapy for immune suppressed patients
US7628980B2 (en)	2000-11-23	2009-12-08	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en)	2000-11-23	2006-08-29	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en)	2000-11-23	2008-11-04	Bavarian Nordic A/S	Modified Vaccinia Ankara virus variant and cultivation method
HU230198B1 (hu)	2000-11-23	2015-10-28	Bavarian Nordic A/S	Módosított Vacciniavírus Ankara-variáns
EP1372708B1 (de)	2001-02-13	2008-06-18	GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY	Impstoffe zur transkutanen immunisierung gegen reisediarrhö
EP1456230A2 (de)	2001-12-04	2004-09-15	Bavarian Nordic A/S	Impfstoff aus der ns1-untereinheit eines flavivirus
EP1420822B2 (de)	2002-04-19	2017-07-05	Bavarian Nordic A/S	Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
AU2003264144C1 (en)	2002-09-05	2009-12-17	Bavarian Nordic A/S	Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
EP1590432A4 (de) *	2003-01-15	2008-05-14	Res Inst For Genetic And Human	Dna-zusammensetzung und ihre verwendung
FR2872170B1 (fr) *	2004-06-25	2006-11-10	Centre Nat Rech Scient Cnrse	Lentivirus non interactif et non replicatif, preparation et utilisations
EP1797189A4 (de) *	2004-09-02	2010-05-19	Qun Chen	Enkapsidationssystem zur herstellung rekombinanter virusähnlicher partikel
GB0526211D0 (en) *	2005-12-22	2006-02-01	Oxford Biomedica Ltd	Viral vectors
US8765462B2 (en)	2007-05-04	2014-07-01	University Health Network	IL-12 immunotherapy for cancer
WO2009070639A1 (en)	2007-11-28	2009-06-04	Irx Therapeutics, Inc.	Method of increasing immunological effect
WO2010009465A2 (en) *	2008-07-18	2010-01-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Htlv-ii vector and methods of use
AU2010248761B2 (en)	2009-05-15	2016-02-11	Irx Therapeutics, Inc.	Vaccine immunotherapy
CN107050430B (zh)	2009-12-08	2021-10-15	伊尔克斯治疗有限公司	逆转朗格汉斯细胞免疫抑制的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5342774A (en) *	1991-05-23	1994-08-30	Ludwig Institute For Cancer Research	Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
KR960701988A (ko) *	1993-04-20	1996-03-28	윌리엄 에스. 로빈슨	세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
US6080408A (en) *	1994-08-22	2000-06-27	Connaught Laboratories Limited	Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles

1997
- 1997-02-20 AP APAP/P/1998/001320A patent/AP964A/en active
- 1997-02-20 EA EA199800746A patent/EA002020B1/ru not_active IP Right Cessation
- 1997-02-20 EP EP97906764A patent/EP0882134B8/de not_active Expired - Lifetime
- 1997-02-20 AT AT97906764T patent/ATE429505T1/de not_active IP Right Cessation
- 1997-02-20 ES ES97906764T patent/ES2324745T3/es not_active Expired - Lifetime
- 1997-02-20 WO PCT/US1997/002933 patent/WO1997031119A1/en not_active Ceased
- 1997-02-20 DE DE69739372T patent/DE69739372D1/de not_active Expired - Lifetime
- 1997-02-20 JP JP09530399A patent/JP2000517290A/ja not_active Ceased
- 1997-02-20 EA EA200100302A patent/EA003554B1/ru not_active IP Right Cessation
- 1997-02-20 CA CA002246359A patent/CA2246359A1/en not_active Abandoned
- 1997-02-20 NZ NZ331369A patent/NZ331369A/en not_active IP Right Cessation
- 1997-02-20 AU AU21369/97A patent/AU726623B2/en not_active Ceased
1998
- 1998-08-18 OA OA9800147A patent/OA10842A/en unknown

Also Published As

Publication number	Publication date
NZ331369A (en)	2001-04-27
EP0882134B1 (de)	2009-04-22
EA002020B1 (ru)	2001-12-24
EP0882134A1 (de)	1998-12-09
AP964A (en)	2001-05-11
EA200100302A1 (ru)	2001-10-22
ATE429505T1 (de)	2009-05-15
DE69739372D1 (de)	2009-06-04
AU726623B2 (en)	2000-11-16
AP9801320A0 (en)	1998-09-30
ES2324745T3 (es)	2009-08-13
CA2246359A1 (en)	1997-08-28
WO1997031119A1 (en)	1997-08-28
AU2136997A (en)	1997-09-10
EP0882134B8 (de)	2009-09-02
JP2000517290A (ja)	2000-12-26
EA199800746A1 (ru)	1999-02-25
EA003554B1 (ru)	2003-06-26

Publication	Publication Date	Title
AP964A (en)	2001-05-11	Methods and compositions for protective and therapeutic genetic immunisation.
EP1035865B1 (de)	2007-09-26	Hiv-1 tat oder deren derivate für prophylaktische und therapeutische impfung
Hanke et al.	1998	Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
Calarota et al.	2004	Enhancement of human immunodeficiency virus type 1‐DNA vaccine potency through incorporation of T‐helper 1 molecular adjuvants
Agadjanyan et al.	1997	An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV
Rollman et al.	2005	The rationale behind a vaccine based on multiple HIV antigens
Radaelli et al.	2003	Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV
Stahl-Hennig et al.	2003	Replication, immunogenicity, and protective properties of live-attenuated simian immunodeficiency viruses expressing Interleukin-4 or interferon-γ
KR100354562B1 (ko)	2002-09-30	원숭이에서 ＳＩＶｍａｃ２３９의 감염에 대한 방어를유도하는 ＡＩＤＳＤＮＡ 백신
Calarota et al.	2004	Approaches for the design and evaluation of HIV-1 DNA vaccines
Bozac et al.	2006	Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses
Cafaro et al.	2009	Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS
AU1971201A (en)	2001-08-09	Methods and compositions for protective and therapeutic genetic immunization
Fultz et al.	2003	Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6 P disease
Ikawait	1994	Role of cell-mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses
EP1144014B1 (de)	2005-07-27	Zusammensetzung und verfahren zur immunisierung gegen ein oder mehrere antigene mittels verschiedener rekombinanter vektoren
Barry	2011	Recombinant vector vaccines for the prevention and treatment of HIV infection
Boyer et al.	2003	Engineering DNA vaccination as an approach to HIV immune therapy
WO2003048366A1 (en)	2003-06-12	Sivmac239 immunogenic plasmids and aids dna vaccine containing the same
MXPA00005325A (en)	2001-12-13	Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination